Search PubMed⌕ Search

Biomedical subjects

V E Pastorova

Publications and source records attributed to V E Pastorova.

At least 19 recordsLinked to original sources
PubMed2003

Prevention of thrombus formation with glyprolines on various models of prethrombotic state and thrombosis in rats.

Peroral administration of peptide Pro-Gly-Pro to 10-11-month-old rats with modeled prethrombotic state normalized functions of the anticoagulation system and produced a potent antiplatelet effect. Peroral administration of Pro-Gly peptide before provocation of thrombin generation and thrombus formation prevented death of animals from thrombosis. Experiments on rats with venous thrombosis induced by stasis and administration of thrombin showed that pretreatment with Pro-Gly peptide decreased the weight of formed thrombi.

Administration, Oral↗
PubMed2000

The effect of prolil-glycil-proline (PGP) peptide and PGP-rich substances on haemostatic parameters of rat blood.

The effect of intravenous and intranasal administration of proline-containing peptide, especially prolil-glycil-proline (PGP), on the haemostatic system of rats was investigated. Tripeptide PGP after single intravenous (0.2, 1.0 and 1.5 mg/kg) or intranasal (0.5 mg/ kg) administration increased (P < 0.05) total fibrinolytic and fibrin depolymerizating (FDA) activities, and tissue plasminogen activator levels (t-PA), and decreased the plasmin inhibitors (PI) and activated factor XIII (factor XIIIa) levels in blood plasma. Repeated daily intranasal administration (5 days) of PGP produced a significant increase of anticoagulant and fibrinolytic activities (P < 0.05), and a decrease of platelet aggregation, PI and factor XIIIa levels in blood plasma. Fibrinogen concentrations remained practically unchanged. Chronic peroral administration of gelatin (protein particularly rich of PGP, prolil-glycil, glycil-proline) as a food supplement significantly increased t-PA level (by 120%) at day 10 and FDA (by 290%) at day 14 in blood plasma. We also observed potent suppression of thrombus formation (venous thrombosis model) by intranasal PGP administration. Therefore, PGP and some PGP-rich substances can be qualified as potent anticoagulant and antithrombotic agents.

Administration, Intranasal↗
PubMed1996

[The modulation of hemostatic reactions in vitro and in vivo by representatives of regulatory peptide families].

Data available in the literature and the author's own findings of the effects of regulatory peptide (RP) and their analogues are summarized. MIF, TRH, and its analog PR-546, the paraopioid RP, leuenkephalin, dalargin, the ACTH analogue Semax, tafcin, thymosine, interleukin-1, vasopressin, oxytocin, bradykinin, defencin, and some proline-containing oligopeptides, such as Pro-Gly, Gly-Pro, Trp-Pro, Pro-Gly-Pro, Gly-Pro-Gly-Gly were studied. A complex of in vitro and in vivo tests identified three groups of RP: 1) neutral ones as to the hemostatic reactions studied; 2) stimulants of hypercoagulation and fibrin polymerization; 3) inhibitors of blood coagulation, increased fibrinolysis, and fibrin demopolymerization. The fibrinolytic and antithrombotic effects of Semax (in vivo), the procoagulative action of defencin, and the enhanced anticoagulant effects in the combinations of Semax-heparin and tafcin (in vivo) attract particular attention. Semax alone and in combination with heparin is recommended for clinical studies in respective hemostatic abnormalities.

Administration, Intranasal↗
PubMed1992

[Fibrinolytic complexes of low-molecular heparin and acetylsalicylic acid].

Complexes of low-molecular heparin with acetylsalicilic acid was formed in vitro when the weight ratio of components was 1:1, 1:5 and 5:1, respectively. All the complexes possessed fibrinolytic and anticoagulating activities. The complex possessed the highest activity when the ratio of heparin to acetylsalicilic acid was 5:1. This complex at a dose 1 mg/200 g of rat weight had the largest thrombolytic effect on the experimental fresh thrombus.

Animals↗
PubMed1990

[A method of determining the anti-, de- and fibrin-polymerization activity of the blood plasma].

The suggested method is based on measuring the changed level of polymerized fibrin monomer and nonstabilized fibrin under the effects of agents enhancing or inhibiting fibrin monomer polymerization. This method permits measurement of plasma specific activity influencing fibrin monomer and unstabilized fibrin polymerization in human and animal blood plasma in health and various diseases involving disorders of hemostasis system, as well as in various drug exposures.

Animals↗
PubMed1990

[Platelet aggregation induced by fibrinmonomer and the effect of the heparin-adrenaline complex or plasmin on this process].

Addition of purified fibrin-monomer in a concentration of 0.5 mg/ml induces aggregation in a suspension of washed rat platelets in the absence of aggregants. Maximum aggregation takes place 1-3 min after fibrin-monomer addition, and then the disaggregation phase follows. Complex heparin compounds with adrenalin or plasmin possessing antipolymerization and fibrinolytic activity with respect to ++non-stabilized fibrin prevent, or to a great extent decrease fibrin-monomer-induced aggregation of washed platelets.

Animals↗
PubMed1990

[Process of fibrin depolymerization and non-enzymatic fibrinolysis in rabbits receiving atherogenic rations with addition of antioxidants].

The rabbits were kept on atherogenic ration for 2 months. This diet contained 0.3 mg/kg of cholesterol. In blood plasma of animals the authors observed a sharply reduced non-enzymatic fibrinolysis and depolymerization activity of non-stabilized fibrin. The addition of antioxidants and alpha-tocopherol (10 + 10 mg/kg) for 1 month to the atherogenic ration protected from the disturbance of the system hemostasis and normalized the depolymerization of non-stabilized fibrin.

Animals↗
PubMed1988

[Effect of a complex mixture of plasma proteins with heparin on the anticoagulation and fibrinolytic activity of the blood plasma in animals following intravenous administration of tissue thromboplastin].

The i.v. administration of 1.5 ml of the heparin complexes with plasma proteins prior to the injection of tissue thromboplastin induced a stronger neutralization of formed thrombin in the blood and higher anticoagulating and fibrinolytic activities in albino rats as compared to the injection of tissue thromboplastin alone.

Animals↗
PubMed1986

[Formation of thrombin and its inactivation by antithrombin III following repeated intravenous injections of tissue thromboplastin in animals].

A breach in the inactivation of thrombin activity by antithrombin III following numerous repeated intravenous injections of tissue thromboplastin to albino rats was established. Seven injections of tissue thromboplastin to animals (at 30-40 min-interval) caused functional exhaustion of anticoagulation system and increased thrombin blood circulation level.

Animals↗
PubMed1986

[Effect of complexes of heparin with plasma proteins on the anticoagulant and fibrinolytic activity of blood].

Mixture of heparin complexes with plasma proteins of the rat blood with no fibrinogen, prothrombin or factors of prothrombin complex obtained either in presence or absence of CaCl2, revealed strong anticoagulating, fibrinolytic, antiaggregating and antipolymerizational activities. 1--2 mM CaCl2 solution increased the enzymatic and non-enzymatic activities of the mixture in vitro. The i.v. administration of the mixture to albino rats potentiated the anticoagulating and fibrinolytic activities of the blood plasma.

Animals↗